For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Prof. Yamanaka, Dr Kondo of PMDA Discuss Toxicity Assessment for iPS Cells-Derived Products
March 7, 2011
- Kyorin Licenses Aclidinium from Almirall
March 7, 2011
- Merck Serono Withdraws MAA for Cladribine
March 7, 2011
- Yakult Ties Up with Proacta to Commercialize Anticancer Drugs
March 7, 2011
- Gov't Bought Vaccines for New Type Flu at \905.50 per Dose
March 7, 2011
- Sanofi-aventis to Transfer Long-Listed Products to Nichi-Iko
March 7, 2011
- Takeda to Develop New Drugs with Unmet Medical Needs at New Research Center
March 7, 2011
- Mochida Recalls Its Generic Heparin Ca
March 7, 2011
- Shionogi to Create GDO to Accelerate Global Development
March 7, 2011
- New Drugs Improve Range of Options for Osteoporosis: 3
March 7, 2011
- PIII Results for Afinitor Published in NEJM
March 7, 2011
- Korosho Approves Norspan, NorLevo after One-Month Delay
March 7, 2011
- Avastin Prolongs PFS in Ovarian Cancer
March 7, 2011
- Nesina Approved for Coadministration with SU and BG: Takeda
March 7, 2011
- JAMS Announces GLs for COI Management
March 7, 2011
- Xeloda Approved for Advanced/Recurrent Stomach Cancer: Chugai
March 7, 2011
- 8 Companies to Withdraw Generic Versions of Dasen
March 7, 2011
- Warfarin Approved for Pediatric Use: Eisai
March 7, 2011
- Korosho Calls on Generic Firms to Apply for New Indications Based on Data from Public Domain
March 7, 2011
- HbA1c to Be Reported in Int'l Units from April 2012 at the Earliest
March 7, 2011
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…